The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Histanaz
Pseudoephedrine HCL, Pyrilamine Maleate · PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1; PYRILAMINE MALEATE 30 mg/1 · Tablet · Oral · Capital Pharmaceutical, LLC
NDC 29978-0129-10 · 100 TABLET in 1 BOTTLE · OTC MONOGRAPH DRUG · View full market →
Medicare Part D
Medicare Part D does not cover over-the-counter drugs — by law it pays only for products requiring a prescription.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- M012
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Pseudoephedrine HCL, Pyrilamine Maleate (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Capital Pharmaceutical, LLC | PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1; PYRILAMINE MALEATE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Histanaz — NDC 29978-0129-10," retrieved September 3, 2026, https://drugdashboards.com/drug/29978012910.
Free to cite with attribution — see how the data is put together.